RxDoctor Payments Data

Barla Thomas

Nurse Practitioner · Henagar, ALNPI 1568600617

Payments from drug & device makers

$3,624in general payments, 2019–2025

Across 218 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$675
  • AbbVie$548
  • GSK$350
  • Lilly USA, LLC$222
  • Takeda Pharmaceuticals U.S.A., Inc.$164
  • Bayer$151
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$3,624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,624 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$26,469
Medicare patients
115
Services billed
1,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$59,713
OzempicSemaglutide45$50,081
JardianceEmpagliflozin21$19,670
Tresiba Flextouch U-200Insulin Degludec17$12,857
FarxigaDapagliflozin Propanediol18$12,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,542
EntrestoSacubitril/Valsartan22$7,892
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$6,463
JanuviaSitagliptin Phosphate11$5,696
Celecoxib25$3,072
Levothyroxine Sodium71$1,414
Montelukast Sodium59$927
Fluticasone Propionate49$801
Pantoprazole Sodium75$697
Atorvastatin Calcium38$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$222$59,71351 claims
Novo NordiskOzempic$675$50,08145 claims
Boehringer IngelheimJardiance$51$19,67021 claims
AstraZenecaFarxiga$74$12,03618 claims
GSKTrelegy Ellipta$350$8,54213 claims
NovartisEntresto$122$7,89222 claims
MerckJanuvia$69$5,69611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Henagar

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →